Fig. 2
m6A modification was reduced in bladder TICs. a Bladder TICs and non-TICs were sorted by FACS with CD44 antibody, and mRNA was extracted for m6A detection. Six bladder tumors were used for TIC enrichment and subsequent m6A detection. b m6A RNA dot blot in bladder TICs and non-TICs. RNA extracted from bladder TICs and non-TICs was examined for m6A modification. Six samples were examined and got similar results. c FACS enriched TICs and non-TICs were stained with m6A and CD44 antibodies, and visualized by confocal microscopy. d Sphere formation was performed, followed by m6A detection using spheres and non-spheres. e Spheres and non-spheres were generated from bladder primary cells and m6A modification was detected. f, g Oncospheres and non-spheres were enriched from bladder cancer sample (f) or T24 cell line (g), followed by immunofluorescence detection of m6A modification. DIC, differential interference contrast. Six samples were examined and similar results were obtained, and sample #1 results were shown. *P < 0.05, **P < 0.01, ***P < 0.001, by two-tailed T test. At least three independent experiments were performed and got similar results